Processa Pharmaceuticals, INC Form 4 insider transactions

Processa Pharmaceuticals' Chief Administrative Officer, Wendy Guy, converted 193 restricted stock units into common stock on January 1, 2026.

Processa Pharmaceuticals' Chief Development Officer, Sian Bigora, acquired 249 shares of common stock through the vesting of restricted stock units.

Processa Pharmaceuticals Director James R. Neal acquired 100,000 Restricted Stock Units and 300,000 stock options, aligning his interests with long-term shareholder value.

Processa Pharmaceuticals director Khoso Baluch acquired 100,000 Restricted Stock Units and 300,000 stock options, aligning his interests with long-term company performance.

Processa Pharmaceuticals Director Geraldine Pannu acquired 100,000 Restricted Stock Units and 300,000 stock options.

Processa Pharmaceuticals director Justin W. Yorke received 100,000 Restricted Stock Units and 300,000 stock options.

Processa Pharmaceuticals, Inc. granted 50,000 Restricted Stock Units and 150,000 stock options to Chief Administrative Officer Wendy Guy, effective October 1, 2025.

Processa Pharmaceuticals, Inc. granted 68,000 Restricted Stock Units and 204,000 Stock Options to Chief Business Strategy Officer Patrick Lin.

Processa Pharmaceuticals' Chief Development Officer, Sian Bigora, was granted 96,000 Restricted Stock Units and 288,000 stock options.

Processa Pharmaceuticals' Chief Financial Officer, Russell Skibsted, was granted 108,000 Restricted Stock Units and 324,000 stock options on October 1, 2025.

Processa Pharmaceuticals, Inc. granted its President of Research & Development, David Young, 111,000 Restricted Stock Units and 333,000 stock options.

Processa Pharmaceuticals CEO George K Ng received 256,000 Restricted Stock Units and 768,000 stock options, vesting over three years.

Processa Pharmaceuticals' Chief Administrative Officer, Wendy Guy, filed an amendment to retract a previously filed Form 4 regarding beneficial ownership.

Processa Pharmaceuticals Director Justin W. Yorke filed an amended Form 4 to retract a previously filed beneficial ownership statement, citing an error.

Processa Pharmaceuticals' Director and President of R&D, David Young, filed an amended Form 4 to retract a previously filed statement of beneficial ownership due to an error.

Processa Pharmaceuticals CFO Russell Skibsted filed an amended Form 4 to correct a previous error regarding his restricted stock unit holdings.

Processa Pharmaceuticals Director Geraldine Pannu filed an amended Form 4 to correct previously reported beneficial ownership of company stock.

Processa Pharmaceuticals CEO George Ng filed an amended Form 4 to correct previously reported beneficial ownership of common stock and warrants.

Processa Pharmaceuticals Director James R. Neal filed an amended Form 4 to correct previously reported beneficial ownership of restricted stock.

Processa Pharmaceuticals' Chief Business Strategy Officer, Patrick Lin, filed an amendment to retract a previously erroneous Form 4 regarding his beneficial ownership of common stock.

Processa Pharmaceuticals' Chief Development Officer, Sian Bigora, filed an amended Form 4 to retract a previously filed beneficial ownership statement.

Processa Pharmaceuticals Director Khoso Baluch filed an amended Form 4 to correct previously reported beneficial ownership of restricted stock.

Processa Pharmaceuticals, Inc. has granted 1,366,046 restricted stock units to Chief Administrative Officer Wendy Guy, aligning executive incentives with long-term company performance.

Processa Pharmaceuticals, Inc. has granted 1,401,650 Restricted Stock Units to Chief Business Strategy Officer Patrick Lin, with a substantial portion contingent on stockholder approval.

Processa Pharmaceuticals' Chief Development Officer, Sian Bigora, was granted 1,659,185 restricted stock units, with vesting tied to future dates and stockholder approval.

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted was granted 1,775,044 Restricted Stock Units, with vesting scheduled through January 2028.

Processa Pharmaceuticals, Inc. has granted 1,813,133 restricted stock units to David Young, President of Research & Development, with vesting scheduled through January 2028 and a portion contingent on stockholder approval.

Processa Pharmaceuticals, Inc. CEO George Ng is set to acquire 1,822,471 Restricted Stock Units on July 24, 2025, under a pre-arranged 10b5-1 plan, with the grant contingent on stockholder approval.

Processa Pharmaceuticals, Inc. Director James R. Neal was granted 175,299 restricted shares, aligning his interests with long-term company performance.

Processa Pharmaceuticals, Inc. Director Khoso Baluch was granted 175,299 shares of restricted stock, aligning his interests with shareholders.